vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $158.6M, roughly 1.0× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -82.0%, a 153.1% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -22.7%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-36.6M).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
PTCT vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $158.6M |
| Net Profit | $-135.0M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | -43.3% | 70.2% |
| Net Margin | -82.0% | 71.2% |
| Revenue YoY | -22.7% | 3661.1% |
| Net Profit YoY | -104.8% | 528.0% |
| EPS (diluted) | $-1.63 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $164.7M | — | ||
| Q3 25 | $211.0M | — | ||
| Q2 25 | $178.9M | — | ||
| Q1 25 | $1.2B | $158.6M | ||
| Q4 24 | $213.2M | $22.6M | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $186.7M | — | ||
| Q1 24 | $210.1M | — |
| Q4 25 | $-135.0M | — | ||
| Q3 25 | $15.9M | — | ||
| Q2 25 | $-64.8M | — | ||
| Q1 25 | $866.6M | $112.9M | ||
| Q4 24 | $-65.9M | $-10.5M | ||
| Q3 24 | $-106.7M | — | ||
| Q2 24 | $-99.2M | — | ||
| Q1 24 | $-91.6M | — |
| Q4 25 | -43.3% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | -19.5% | — | ||
| Q1 25 | 82.5% | 70.2% | ||
| Q4 24 | -76.2% | -60.4% | ||
| Q3 24 | -27.7% | — | ||
| Q2 24 | -21.5% | — | ||
| Q1 24 | -21.6% | — |
| Q4 25 | -82.0% | — | ||
| Q3 25 | 7.5% | — | ||
| Q2 25 | -36.3% | — | ||
| Q1 25 | 73.7% | 71.2% | ||
| Q4 24 | -30.9% | -46.4% | ||
| Q3 24 | -54.2% | — | ||
| Q2 24 | -53.1% | — | ||
| Q1 24 | -43.6% | — |
| Q4 25 | $-1.63 | — | ||
| Q3 25 | $0.20 | — | ||
| Q2 25 | $-0.83 | — | ||
| Q1 25 | $10.04 | $1.90 | ||
| Q4 24 | $-0.85 | $-0.15 | ||
| Q3 24 | $-1.39 | — | ||
| Q2 24 | $-1.29 | — | ||
| Q1 24 | $-1.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-205.3M | $350.1M |
| Total Assets | $2.9B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | $274.8M | ||
| Q4 24 | $1.1B | $128.0M | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $884.8M | — |
| Q4 25 | $-205.3M | — | ||
| Q3 25 | $-155.8M | — | ||
| Q2 25 | $-206.5M | — | ||
| Q1 25 | $-185.8M | $350.1M | ||
| Q4 24 | $-1.1B | $229.0M | ||
| Q3 24 | $-1.1B | — | ||
| Q2 24 | $-980.2M | — | ||
| Q1 24 | $-893.9M | — |
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.7B | $406.9M | ||
| Q4 24 | $1.7B | $271.6M | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | $131.8M |
| Free Cash FlowOCF − Capex | $-36.6M | $131.7M |
| FCF MarginFCF / Revenue | -22.3% | 83.0% |
| Capex IntensityCapex / Revenue | 1.4% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.3M | — | ||
| Q3 25 | $-66.3M | — | ||
| Q2 25 | $-58.3M | — | ||
| Q1 25 | $870.1M | $131.8M | ||
| Q4 24 | $-30.0M | $-23.2M | ||
| Q3 24 | $-77.0M | — | ||
| Q2 24 | $-71.5M | — | ||
| Q1 24 | $70.8M | — |
| Q4 25 | $-36.6M | — | ||
| Q3 25 | $-69.7M | — | ||
| Q2 25 | $-59.6M | — | ||
| Q1 25 | $868.4M | $131.7M | ||
| Q4 24 | $-33.8M | $-23.2M | ||
| Q3 24 | $-77.5M | — | ||
| Q2 24 | $-78.8M | — | ||
| Q1 24 | $61.2M | — |
| Q4 25 | -22.3% | — | ||
| Q3 25 | -33.1% | — | ||
| Q2 25 | -33.3% | — | ||
| Q1 25 | 73.8% | 83.0% | ||
| Q4 24 | -15.8% | -102.7% | ||
| Q3 24 | -39.4% | — | ||
| Q2 24 | -42.2% | — | ||
| Q1 24 | 29.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.1% | 0.1% | ||
| Q4 24 | 1.8% | 0.2% | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 4.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | -4.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.00× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
